{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:03:51Z","timestamp":1790964231972,"version":"4.1.0"},"reference-count":67,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Mass drug administration (MDA) has been implemented as a tool to eliminate lymphatic filariasis. Acceptability among susceptible populations is crucial to achieving MDA effective coverage. This systematic review aims to present and systematically determine the factors associated with the acceptability of MDA. Articles related to factors associated with acceptability were collected electronically from three different databases (Scopus, Web of Science, and PubMed). Four pairs of independent reviewers screened the titles and abstracts of the collected data, stored in EndnoteX7, against the inclusion criteria. Afterwards, the included articles have been critically appraised to assess the quality of the studies using the Mixed Method Appraisal Tool (MMAT). Of the 68 articles identified, 11 were included in the final review. Knowledge, awareness, attitude and perceptions, communications, delivery and accessibility of MDA, gender, and age are the factors associated with MDA acceptability. Community acceptance remains a challenge in the implementation of MDA. To expand MDA coverage in all endemic countries, there is a strong need to address the factors influencing community acceptance of MDA.<\/jats:p>","DOI":"10.3390\/ijerph191912971","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T21:07:11Z","timestamp":1665436031000},"page":"12971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review"],"prefix":"10.3390","volume":"19","author":[{"given":"Ahmad Farid Nazmi","family":"Abdul Halim","sequence":"first","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzulfitree","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Ling","family":"Miaw Yn","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-9420","authenticated-orcid":false,"given":"Noor Azreen","family":"Masdor","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-7658","authenticated-orcid":false,"given":"Nurfatehar","family":"Ramly","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahayu","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-0787","authenticated-orcid":false,"given":"Thinakaran","family":"Kandayah","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-6532","authenticated-orcid":false,"given":"Mohd Rohaizat","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia"},{"name":"Borneo Medical and Health Research Centre, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-0340","authenticated-orcid":false,"given":"Rahmat","family":"Dapari","sequence":"additional","affiliation":[{"name":"Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","article-title":"Lymphatic Filariasis and Onchocerciasis","volume":"376","author":"Taylor","year":"2010","journal-title":"Lancet"},{"key":"ref_2","unstructured":"WHO (2022). Lymphatic Filariasis, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-3156.2000.00620.x","article-title":"The Global Programme to Eliminate Lymphatic Filariasis","volume":"5","author":"Ottesen","year":"2000","journal-title":"Trop. Med. Int. Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14656566.6.2.179","article-title":"Treatment Strategies Underpinning the Global Programme to Eliminate Lymphatic Filariasis","volume":"6","author":"Gyapong","year":"2005","journal-title":"Expert Opin Pharmacother."},{"key":"ref_5","unstructured":"WHO (2017). Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(04)00973-9","article-title":"Mathematical Modelling and the Control of Lymphatic Filariasis","volume":"4","author":"Michael","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1086\/378354","article-title":"Prospects for Elimination of Bancroftian Filariasis by Mass Drug Treatment in Pondicherry India: A Simulation Study","volume":"188","author":"Stolk","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_8","unstructured":"WHO (2011). Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes, WHO."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Niles, R.A., Thickstun, C.R., Cox, H., Dilliott, D., Burgert-Brucker, C.R., Harding-Esch, E.M., Clementson, N., Sampson, A., Alexandre, J.S., and Morice Trejos, A.C. (2021). Assessing Factors Influencing Communities\u2019 Acceptability of Mass Drug Administration for the Elimination of Lymphatic Filariasis in Guyana. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009596"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Krentel, A., Fischer, P.U., and Weil, G.J. (2013). A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002447"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sekhon, M., Cartwright, M., and Francis, J.J. (2017). Acceptability of Healthcare Interventions: An Overview of Reviews and Development of a Theoretical Framework. BMC Health Serv. Res., 17.","DOI":"10.1186\/s12913-017-2031-8"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hill, J., Hoyt, J., Achieng, F., Ouma, P., L\u2019lanziva, A., Kariuki, S., Desai, M., and Webster, J. (2016). User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150259"},{"key":"ref_13","first-page":"643","article-title":"The Acceptability of HIV Immunization: Examining Vaccine Characteristics as Determining Factors","volume":"13","author":"Liau","year":"2001","journal-title":"AIDS Care\u2014Psychol Socio-Med. Asp AIDS\/HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-4405(90)90007-T","article-title":"Acceptability of Time-out: The Influence of Problem Behavior Severity, Interventionist, and Reported Effectiveness","volume":"28","author":"Tingstrom","year":"1990","journal-title":"J. Sch. Psychol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Munn, Z., Stern, C., Aromataris, E., Lockwood, C., and Jordan, Z. (2018). What Kind of Systematic Review Should i Conduct? A Proposed Typology and Guidance for Systematic Reviewers in the Medical and Health Sciences. BMC Med. Res. Methodol., 18.","DOI":"10.1186\/s12874-017-0468-4"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-Duplication of Database Search Results for Systematic Reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J. Med. Libr. Assoc."},{"key":"ref_18","first-page":"285","article-title":"The Mixed Methods Appraisal Tool (MMAT) Version 2018 for Information Professionals and Researchers","volume":"34","author":"Hong","year":"2018","journal-title":"Educ. Inf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.18051\/UnivMed.2016.v35.119-127","article-title":"Directly Observed Treatment Increases Drug Compliance in Lymphatic Filariasis Mass Drug Administration","volume":"35","author":"Rosanti","year":"2016","journal-title":"Universa Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.47203\/IJCH.2018.v30i03.017","article-title":"Mass Drug Administration (MDA) for Elimination of Lymphatic Filariasis: Experiences from Nayagarh District of Odisha, India","volume":"30","author":"Bhatia","year":"2018","journal-title":"Indian J. Community Health"},{"key":"ref_21","first-page":"113","article-title":"Factors Determining Drug Uptake during Mass Drug Administration in Banyuasin District, South Sumatera, Indonesia","volume":"8","author":"Putri","year":"2019","journal-title":"Int. J. Recent Technol. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-5070.105175","article-title":"Factors Determining Noncompliance to Mass Drug Administration for Lymphatic Filariasis Elimination","volume":"2","author":"Nujum","year":"2012","journal-title":"Trop. Parasitol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13071-018-2689-8","article-title":"The Role of Gender Relations in Uptake of Mass Drug Administration for Lymphatic Filariasis in Alor District, Indonesia","volume":"11","author":"Krentel","year":"2018","journal-title":"Parasites Vectors"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-3305-1-14","article-title":"Factors Associated with the Acceptance of Mass Drug Administration for the Elimination of Lymphatic Filariasis in Agusan Del Sur, Philippines","volume":"1","author":"Amarillo","year":"2008","journal-title":"Parasites Vectors"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1179\/000349804X3135","article-title":"Factors Associated with Participation in a Campaign of Mass Treatment against Lymphatic Filariasis, in Leogane, Haiti","volume":"98","author":"Mathieu","year":"2004","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Adekeye, O., Ozano, K., Dixon, R., Elhassan, E.O., Lar, L., Schmidt, E., Isiyaku, S., Okoko, O., Thomson, R., and Theobald, S. (2020). Mass Administration of Medicines in Changing Contexts: Acceptability, Adaptability and Community Directed Approaches in Kaduna and Ogun States, Nigeria. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008857"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1017\/S0021932012000466","article-title":"Will Mass Drug Administration Eliminate Lymphatic Filariasis? Evidence from Northern Coastal Tanzania","volume":"45","author":"Parker","year":"2013","journal-title":"J. Biosoc. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kisoka, W.J., Simonsen, P.E., Malecela, M.N., Tersb\u00f8l, B.P., Mushi, D.L., and Meyrowitsch, D.W. (2014). Factors Influencing Drug Uptake during Mass Drug Administration for Control of Lymphatic Filariasis in Rural and Urban Tanzania. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109316"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4269\/ajtmh.12-0491","article-title":"Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program","volume":"89","author":"Bradley","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2883-4-7","article-title":"Defining the Cost of the Egyptian Lymphatic Filariasis Elimination Programme","volume":"4","author":"Ramzy","year":"2005","journal-title":"Filaria J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/0975-1483.96624","article-title":"Drug Attitude and Adherence: A Qualitative Insight of Patients with Hypertension","volume":"4","author":"Saleem","year":"2012","journal-title":"J. Young Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s13071-014-0545-z","article-title":"Lymphatic Filariasis in Peninsular Malaysia: A Cross-Sectional Survey of the Knowledge, Attitudes, and Practices of Residents","volume":"7","author":"Nor","year":"2014","journal-title":"Parasites Vectors"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/trstmh\/trab132","article-title":"Prevalence and Risk Factors for Positive Lymphatic Filariasis Antibody in Sabah, Malaysia: A Cross-Sectional Study","volume":"116","author":"Zakaria","year":"2022","journal-title":"Trans. R Soc. Trop. Med. Hyg."},{"key":"ref_34","first-page":"81","article-title":"Medication Adherence of Elderly with Hypertension and\/OrDiabetes-Mellitus and Its\u2019 Influencing Factors","volume":"21","author":"Kim","year":"2011","journal-title":"Korean J. Clin. Pharm."},{"key":"ref_35","first-page":"124","article-title":"Factors Determining Non-Compliance to Mass Drug Administration for Lymphatic Filariasis Elimination in Endemic Districts of Nepal","volume":"12","author":"Adhikari","year":"2014","journal-title":"J. Nepal Health Res. Counc."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Njomo, D.W., Amuyunzu-Nyamongo, M., Magambo, J.K., and Njenga, S.M. (2012). The Role of Personal Opinions and Experiences in Compliance with Mass Drug Administration for Lymphatic Filariasis Elimination in Kenya. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048395"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2049-9957-3-31","article-title":"Mass Drug Administration for Lymphatic Filariasis Elimination in a Coastal State of India: A Study on Barriers to Coverage and Compliance","volume":"3","author":"Hussain","year":"2014","journal-title":"Infect. Dis. Poverty"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Clement, Y.N., Morton-Gittens, J., Basdeo, L., Blades, A., Francis, M.-J., Gomes, N., Janjua, M., and Singh, A. (2007). Perceived Efficacy of Herbal Remedies by Users Accessing Primary Healthcare in Trinidad. BMC Complement. Altern. Med., 7.","DOI":"10.1186\/1472-6882-7-4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41182-021-00305-3","article-title":"Evaluating Context-Specific Evidence-Based Quality Improvement Intervention on Lymphatic Filariasis Mass Drug Administration in Northern Ghana Using the RE-AIM Framework","volume":"49","author":"Manyeh","year":"2021","journal-title":"Trop. Med. Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2883-6-1","article-title":"Qualitative Analysis of the Impact of a Lymphatic Filariasis Elimination Programme Using Mass Drug Administration on Misima Island, Papua New Guinea","volume":"6","author":"Wynd","year":"2007","journal-title":"Filaria J."},{"key":"ref_41","first-page":"25","article-title":"Elimination of Lymphatic Filariasis: Current Perspectives on Mass Drug Administration","volume":"9","author":"Owusu","year":"2018","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(12)60159-7","article-title":"Will Increased Funding for Neglected Tropical Diseases Really Make Poverty History?","volume":"379","author":"Allen","year":"2012","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Demb\u00e9l\u00e9, M., Bamani, S., Demb\u00e9l\u00e9, R., Traor\u00e9, M.O., Goita, S., Traor\u00e9, M.N., Sidibe, A.K., Sam, L., Tuinsma, M., and Toubali, E. (2012). Implementing Preventive Chemotherapy through an Integrated National Neglected Tropical Disease Control Program in Mali. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001574"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.5001\/omj.2020.40","article-title":"Implications of Language Barriers for Healthcare: A Systematic Review","volume":"35","author":"Almutairi","year":"2020","journal-title":"Oman Med. J"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ipa, M., Astuti, E., Ridwan, W., and Soerachman, R. (2019, January 3\u20134). Qualitative Study: Leverage and Barrier Factors of Mass Drug Administration for Lymphatic Filariasis Elimination Program in Tangerang and Subang Regency. Proceedings of the 5th Universitas Ahmad Dahlan Public Health Conference (UPHEC 2019), Yogyakarta, Indonesia.","DOI":"10.2991\/ahsr.k.200311.022"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/jan.12361","article-title":"Factors Associated with Gender Differences in Medication Adherence: A Longitudinal Study","volume":"70","author":"Chen","year":"2014","journal-title":"J. Adv. Nurs."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/jwh.2012.3972","article-title":"Influence of Patient Sex and Gender on Medication Use, Adherence, and Prescribing Alignment with Guidelines","volume":"23","author":"Manteuffel","year":"2014","journal-title":"J. Womens Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women Encounter ADRs More Often than Do Men","volume":"64","author":"Zopf","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","unstructured":"Feinberg, L., Reinhard, S., Houser, A., and Choula, R. (2010). Valuing the Invaluable: 2011 Update the Growing Contributions and Costs of Family Caregiving, AARP Public Policy Institute. Insight Issues."},{"key":"ref_50","first-page":"207","article-title":"Women and Men Report Different Behaviours in, and Reasons for Medication Non-Adherence: A Nationwide Swedish Survey","volume":"10","author":"Bingefors","year":"2012","journal-title":"Pharm Pract."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4088\/JCP.10m06090blu","article-title":"Pregnancy as a Major Determinant for Discontinuation of Antidepressants: An Analysis of Data from The Health Improvement Network","volume":"72","author":"Petersen","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_52","first-page":"44","article-title":"Abrupt Discontinuation of Psychotropic Drugs during Pregnancy: Fear of Teratogenic Risk and Impact of Counselling","volume":"26","author":"Einarson","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e000512","DOI":"10.1136\/bmjgh-2017-000512","article-title":"20 Years of Gender Mainstreaming in Health: Lessons and Reflections for the Neglected Tropical Diseases Community","volume":"2","author":"Theobald","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Widawati, M., Astuti, E.P., Ruliansyah, A., and Yuliasih, Y. (2019, January 3\u20134). Sociodemographic, Knowledge, and Attitude Determinants of Lymphatic Filariasis Medication Adherence in Subang, Indonesia. Proceedings of the 5th Universitas Ahmad Dahlan Public Health Conference (UPHEC 2019), Yogyakarta, Indonesia.","DOI":"10.2991\/ahsr.k.200311.001"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rilkoff, H., Tukahebwa, E.M., Fleming, F.M., Leslie, J., and Cole, D.C. (2013). Exploring Gender Dimensions of Treatment Programmes for Neglected Tropical Diseases in Uganda. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002312"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13071-021-04583-y","article-title":"Risk Factors for Lymphatic Filariasis and Mass Drug Administration Non-Participation in Mandalay Region, Myanmar","volume":"14","author":"Dickson","year":"2021","journal-title":"Parasit Vectors"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e17825","DOI":"10.1097\/MD.0000000000017825","article-title":"Impact of Number of Medications and Age on Adherence to Antihypertensive Medications: A Nationwide Population-Based Study","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Njomo, D.W., Kibe, L.W., Kimani, B.W., Okoyo, C., Omondi, W.P., and Sultani, H.M. (2020). Addressing Barriers of Community Participation and Access to Mass Drug Administration for Lymphatic Filariasis Elimination in Coastal Kenya Using a Participatory Approach. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008499"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/pch\/13.1.19","article-title":"Adherence to Treatment in Adolescents","volume":"13","author":"Taddeo","year":"2008","journal-title":"Paediatr. Child Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2883-6-7","article-title":"Delivery Strategy of Mass Annual Single Dose DEC Administration to Eliminate Lymphatic Filariasis in the Urban Areas of Pondicherry, South India: 5 Years of Experience","volume":"6","author":"Nandha","year":"2007","journal-title":"Filaria J."},{"key":"ref_61","first-page":"9","article-title":"The survey of important socio- economic & cltural variables influencing self-medication","volume":"8","author":"Tavakoli","year":"2001","journal-title":"Daneshvar Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/agm2.12045","article-title":"Factors Associated with Medication Adherence in Older Patients: A Systematic Review","volume":"1","author":"Smaje","year":"2018","journal-title":"Aging Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Krentel, A., Damayanti, R., Titaley, C.R., Suharno, N., Bradley, M., and Lynam, T. (2016). Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two \u2018Endgame\u2019 Districts in Indonesia Using Micronarrative Surveys. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0005027"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-3156.2004.01247.x","article-title":"Coverage, Compliance and Some Operational Issues of Mass Drug Administration during the Programme to Eliminate Lymphatic Filariasis in Orissa, India","volume":"9","author":"Babu","year":"2004","journal-title":"Trop. Med. Int. Health"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Khaemba, C., Barry, A., Omondi, W.P., Bota, K., Matendechero, S., Wandera, C., Siyoi, F., Kirui, E., Oluka, M., and Nambwa, P. (2021). Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030264"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1478-4505-9-3","article-title":"Does Mass Drug Administration for the Integrated Treatment of Neglected Tropical Diseases Really Work? Assessing Evidence for the Control of Schistosomiasis and Soil-Transmitted Helminths in Uganda","volume":"9","author":"Parker","year":"2011","journal-title":"Health Res. Policy Syst."},{"key":"ref_67","unstructured":"WHO (2017). Towards Universal Coverage for Preventive Chemotherapy for Neglected Tropical Diseases: Guidance for Assessing \u201cWho Is Being Left behind and Why\u201d, WHO. WHO\/WFC\/17.3."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:23Z","timestamp":1760143763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":67,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijerph191912971"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191912971","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]}}}